Search results for " Antico"

Unmanned Aerial Vehicle (UAV) Survey with Commercial-Grade Instruments: A Case Study from the Eastern Ḫabur Archaeological Survey, Iraq

2018

Low-altitude photography in archaeology is now common practice at the scale of excavations; however, landscape-scale applications are a relatively new endeavor with promising analytical potential. From 2014–2016, an unmanned aerial vehicle (UAV) with a mounted camera was used to document sites recorded as part of the Eastern Ḫabur Archaeological Survey (EḪAS), an archaeological reconnaissance project in western Dohuk Province, Iraqi Kurdistan. The EḪAS team documented over 70 archaeological sites with the UAV, from single-phase artifact scatters, to archaeological remains with standing architecture, to tells that cover more than 30 hectares. Representative examples from this survey are pres…

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

2019

Background Time in therapeutic range (TTR) measures the quality of vitamin K antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized SAMe-TT2-R2 score (≥2 vs. < 2 points) can predict if adequate TTR is unlikely to be achieved. Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism (VTE) randomized to the warfarin arm of the Hokusai-VTE trial. Patients and Methods A total of 3,874 patients were included in the primary analysis (day 31–180 from randomization). The efficacy and safety outcomes were symptomatic recurrent VTE and major or clinically relevant non-major bleeding. Results The rates of recurrent VTE and bleeding events we…

The Novel Oral Anticoagulants for Acute Venous Thromboembolism: Is Warfarin Dead?

2017

The direct oral anticoagulants (DOACs) have been compared with parenteral anticoagulants and vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) in several robust studies. DOACs have shown similar efficacy in preventing recurrent VTE and significant reductions in critical site (intracranial) bleeding, fatal bleeding, major and nonmajor bleeding. Warfarin and other VKAs are not dead as treatment modalities for VTE. A better way to describe the current situation is to use a boxing expression, “down but not out.” VKAs and parenteral anticoagulants still have a role to play in the management of VTE in several clinical settings. In indications where DOACs can be used, …

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.

2020

AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis

2018

AbstractAtherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagulation proteases, interacting with circulating cells and in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed with audience members and the results of these discussions were incorporated in the final document that presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following five topics: 1. Risk factors, biomarkers and plaque inst…

Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies

2016

Objective: To test previous signals of a risk of orofacial cleft (OC) and clubfoot with exposure to the antiepileptic lamotrigine, and to investigate risk of other congenital anomalies (CA).Methods: This was a population-based case–malformed control study based on 21 EUROCAT CA registries covering 10.1 million births (1995–2011), including births to 2005 in which the clubfoot signal was generated and a subsequent independent study population of 6.3 million births. A total of 226,806 babies with CA included livebirths, stillbirths, and terminations of pregnancy following prenatal diagnosis. First-trimester lamotrigine monotherapy exposure in OC cases and clubfoot cases was compared to other …

IL SITO DI SHIYUK TAHTANI: DATI ANTROPOLOGICI DALLA CAMPAGNA DI SCAVO 2009

2009

UN CIMITERO RUPESTRE DI EPOCA TARDOANTICA IN SICILIA: STUDIO INTERDISCIPLINARE DELL’AMBIENTE E DEI REPERTI ARCHEOLOGICI.

2012

GIOVANNI CARBONARA. ARCHITETTURA D'OGGI E RESTAURO: UN CONFRONTO ANTICO-NUOVO

2012

Architettura di oggi e restauro dell'antico sono temi largamente dibattuti per quanto riguarda le modalità di approccio. Non esistono leggi a priori o regole da seguire, ma si è sempre cercato di stabilire parametri e categorie per uniformare le proprie scelte. All'interno di tale panorama inevitabilmente si delineano correnti di pensiero diverse, talvolta anche contrastanti, caratterizzate ognuna da un diverso modo di interpretare il rapporto tra l'antico e il nuovo. Proprio all'interno di tale dialettica si inserisce il pensiero di numerosi architetti, fra cui quello di Giovanni Carbonara, che, attraverso il presente testo, ha voluto presentare una variegata rassegna delle possibili modal…

Stroke Incidence and Death in Atrial Fibrillation Patients Newly Treated with Direct Oral Anticoagulants.

2021

Amélie Gabet,1 Edouard Chatignoux,1 Clémence Grave,1 Alexandre Vallée,2 Philippe Tuppin,3 Yannick Béjot,4 Valérie Olié1 1French Public Health Agency, Saint-Maurice, France; 2Diagnosis and Therapeutic Center, Hotel Dieu, AP-HP, University Paris Descartes, Paris, France; 3General Health Insurance Scheme (Caisse Nationale d’Assurance Maladie), Paris, France; 4Dijon Stroke Registry, EA4184, University Hospital and Medical School of Dijon, University of Burgundy, Dijon, FranceCorrespondence: Amélie GabetFrench Public Health Agency, 14 rue du Val d’Osne, Saint Maurice, 94410, FranceTel +33155125164Fax…